OncXerna Therapeutics

Listen to Mark Uhlik, Ph.D., present on the Xerna TME Panel and data recently presented at ESMO at QIAGEN’s Innovation Forum 2022! #cancerresearch youtu.be/Qr6sEbMtLfc

Today at @myESMO (ESMO), we announced new Xerna™ TME Panel Biomarker Data from Retrospective Analysis of Results from a Randomized Phase 2 Trial Evaluating Anti-PD-1 Maintenance Therapy in Esophagogastric Adenocarcinoma. Read more bit.ly/3eAeQx9.

We’re excited to announce our first patient dosed in a Phase 2 basket trial of navicixizumab! Read more at bit.ly/3x4c6i7

Be sure to check out article in Nature Biopharma Dealmakers, just released today! go.nature.com/3COEZTc #ai #artificialintelligence #medicine #pipeline #biopharma

OncXerna Therapeutics supports the @MensHlthNetwork in their goal to increase awareness of men’s health issues on a global level. Talk to your healthcare provider about scheduling the appointments you need to keep yourself in good health! #MensHealthWeek

OncXerna Therapeutics congratulates Dr. Elizabeth Gerstner from Mass General Cancer Center on poster presented at @ASCO. Read more here: bit.ly/3xcjtDc, bit.ly/3MrSDMR #ASCO22 #glioblastoma #bavi

OncXerna Therapeutics celebrates and appreciates the hard work and compassion of oncology nurses! @oncologynursing #OncologyNursingMonth

OncXerna Therapeutics would like to thank all the investigators, site personnel, patients, and families that participate in cancer research! #NationalCancerResearchMonth #NCRM22 #ClinicalTrialsDay #CTD2022

OncXerna Therapeutics wants to expand awareness for ovarian cancer and recognize World Ovarian Cancer Day. #WorldOvarianCancerDay #OvarianCancerAwareness #OvarianCancer #WOCD2022

It was great to have the entire team in Waltham this past week! #team #teammeeting #teambonding

Today, Laura Benjamin, PhD, will be at the 12th Annual Clinical Biomarker and CDx Europe Summit in London. @WorldCDx #PrecisionMedicine #Biomarker

OncXerna Therapeutics is proud to announce @JCO_ASCO publication featuring Phase 1b data of navicixizumab plus paclitaxel in ovarian cancer. Read more here: bit.ly/3Oq2btZ, bit.ly/3L4wFzE #OvarianCancer #XernaTME #navi

Today in Washington, DC at the #WorldVaccineCongress, OncXerna's Founder/CEO, Laura Benjamin, PhD, will moderate a keynote panel on advances in precision medicine tools informing strategies for mono and combination therapies. #WVCDC #WVCUSA #PrecisionMedicine @VaccineNation

Please join us in celebrating OncXerna Therapeutics’ 4-year anniversary! #PrecisionMedicine #CompanyAnniversary

OncXerna Therapeutics highlights the Xerna™ TME Panel’s prognostic and predictive value across indications and therapeutic classes at the AACR Annual Meeting. Read more here: bit.ly/3jkPbYu @AACR #AACR22 #AACR2022 #XernaTMEPanel

March is National Colorectal Cancer Awareness Month. With regular screening, most polyps can be found and removed before they turn into cancer. Early detection leads to better outcomes! #ColorectalCancerAwarenessMonth #ColonCancerAwareness #ColonCancer #CancerAwareness

March 18-21, Kerry Culm, Ph.D., Vice President of Clinical Development at OncXerna Therapeutics, will present at the 2022 Annual Meeting on Women’s Cancer hosted by @SGO_org in Phoenix, Arizona. View our poster here: bit.ly/36rf9Gy #SGO #SGOmtg #WomensCancer

Celebrating the women of OncXerna Therapeutics on International Women’s Day! #InternationalWomensDay #InternationalWomensDay2022

Today, March 3ʳᵈ, OncXerna Therapeutics’ Head of Research and Biomarker Discovery, Mark Uhlik, will be presenting at the 3ʳᵈ Annual Oncology Research Information Exchange Network (ORIEN) Scientific Retreat hosted by @M2GEN in St. Pete Beach, FL. #PrecisionMedicine #Oncology

We're excited to share that StartUs Insights evaluated 479 companies globally and recognized OncXerna Therapeutics as one of the top 5 precision medicine startups. Read more here: bit.ly/3H103UG #PrecisionMedicine